ストックスクリーナーアプリを入手
0.6521
0.32%
0.0021
プレマーケット:
.66
0.0079
+1.21%
前日終値:
$0.65
開ける：
$0.67
24時間の取引高:
484.47K
Relative Volume:
0.54
時価総額：
$76.61M
収益：
-
当期純損益:
$-30.54M
株価収益率:
-0.4207
EPS:
-1.55
ネットキャッシュフロー:
$-18.30M
1週間 パフォーマンス:
+1.89%
1か月 パフォーマンス:
+18.89%
6か月 パフォーマンス:
+30.39%
1年 パフォーマンス:
-41.78%
1日の値動き範囲:
$0.65
$0.67
1週間の範囲:
$0.6301
$0.67
52週間の値動き範囲:
$0.202
$1.21
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
名前
Unicycive Therapeutics Inc
セクター
電話
650-384-0642
住所
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
UNCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
0.6521 | 76.61M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-21 | 開始されました | Guggenheim | Buy |
| 2024-04-04 | 開始されました | Piper Sandler | Overweight |
Unicycive Therapeutics Inc (UNCY) 最新ニュース
Geode Capital Management LLC Acquires 122,089 Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Defense World
Insider’s View: Deciphering Unicycive Therapeutics Inc (UNCY)’s Financial Health Through Ratios - DWinneX
Unicycive Therapeutics Inc (UNCY)’s stock performance: a year in review - uspostnews.com
XTX Topco Ltd Raises Stock Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Defense World
Ratios Uncovered: Breaking Down Unicycive Therapeutics Inc (UNCY)’s Trailing Twelve Months Metrics - DWinneX
What is the investor’s view on Unicycive Therapeutics Inc (UNCY)? - uspostnews.com
Unicycive Therapeutics (NASDAQ:UNCY) Coverage Initiated by Analysts at Guggenheim - Defense World
Guggenheim Initiates Coverage of Unicycive Therapeutics (UNCY) with Buy Recommendation - Nasdaq
Guggenheim Initiates Unicycive Therapeutics at Buy With $6 Price Target - marketscreener.com
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update - ADVFN
HC Wainwright Reiterates “Buy” Rating for Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
H.C. Wainwright maintains Unicycive Buy rating, $7.50 target By Investing.com - Investing.com Canada
Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate - TipRanks
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis - GlobeNewswire
Breakthrough: Unicycive's New Kidney Drug Cuts Pills in Half, 98% of Patients Report Easy Use - Stock Titan
Unicycive Therapeutics Inc Inc. (UNCY) Price Performance: A Technical Analysis Perspective - investchronicle.com
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - ACCESS Newswire
HC Wainwright Issues Pessimistic Estimate for UNCY Earnings - Defense World
UNCY FY2025 EPS Lifted by Brookline Capital Management - Defense World
Brookline Capital Management Weighs in on UNCY Q1 Earnings - Defense World
HC Wainwright Issues Positive Forecast for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price - Defense World
Unicycive stock target raised to $7.50 by H.C. Wainwright - Investing.com Canada
Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS - MarketBeat
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive Look: Unicycive Unveils Latest Kidney Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Noble Financial Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY) - The Globe and Mail
Unicycive Therapeutics, Inc. SEC 10-K Report - TradingView
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
FDA to Review Unicycive's Kidney Disease Drug in June 2025: Key Financial Updates - Stock Titan
Unicycive Therapeutics Inc. (UNCY) reports earnings - qz.com
Unicycive Approaches Its First Approval, But In A Competitive Space - insights.citeline.com
Targeting Pressing Unmet Needs in Kidney Diseases with Unicycive Therapeutics CEO Dr. Shalabh Gupta - iHeart
Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday - Defense World
Unicycive to Highlight Patient Reported Outcomes Data at - GlobeNewswire
Revolutionary Dialysis Treatment Cuts Pill Burden in Half: Key Clinical Data Coming - StockTitan
Unicycive Therapeutics Inc (NASDAQ:UNCY) stock: Is this a flash in the pan today? - US Post News
Unicycive Therapeutics Inc (NASDAQ: UNCY) Is One Of The Hottest Stocks Right Now. - Stocks Register
Unicycive reports potential kidney disease treatment advance By Investing.com - Investing.com Nigeria
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 - The Manila Times
Unicycive reports potential kidney disease treatment advance - Investing.com
Unicycive Therapeutics Announces the Publication of - GlobeNewswire
Groundbreaking Kidney Disease Treatment Shows 41% Better ResultsCan This Change Dialysis Patient Care? - StockTitan
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 51.6% in January - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex
Investing in Unicycive Therapeutics Inc [UNCY]: What You Must Know - Knox Daily
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Is Expected To Breakeven In The Near Future - Simply Wall St
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Short Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Rises By 25.4% - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Gains Momentum, Closing at 0.61 - The Dwinnex
Unicycive Therapeutics' (UNCY) Buy Rating Reiterated at HC Wainwright - MarketBeat
Unicycive highlights challenges in phosphate management - MSN
Unicycive Therapeutics Inc (UNCY) 財務データ
収益
当期純利益
現金流量
EPS
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):